Passage Bio Stock Math Operators Price Series Summation

PASG Stock  USD 8.72  0.21  2.47%   
The math operators view organizes Price Series Summation operator and supporting indicators around Passage Bio and CASI Pharmaceuticals. It emphasizes relative price relationships between Passage Bio and CASI Pharmaceuticals while keeping volatility, risk, and performance context in view.

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Passage Bio Price Series Summation is a cross summation of Passage Bio price series and its benchmark/peer.

Passage Bio Technical Analysis Modules

Most technical analysis of Passage Bio help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Passage from various momentum indicators to cycle indicators. When you analyze Passage charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Passage Bio Inc

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. Liquidity and trading activity can influence how quickly new information is reflected in Passage Bio's price. Lower liquidity may increase execution variability. Passage Bio has market cap of 27.3 M, ROE of -113.78%.

Methodology

Unless otherwise specified, financial data for Passage Bio is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Passage (USA Stocks:PASG) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We primarily rely on public filings and market reference sources, including disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data is normalized for analytical consistency across reporting formats. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Passage Bio is covered by 5 analysts. 2 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include RBC Capital Markets, Barclays, HSBC Global Research, Wells Fargo Securities, Bank of America Securities, among others. Updates may occur throughout the day.


Align your values with your investing style

Using Passage Bio inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Macroaxis Index Idea
Macroaxis Index
Invested few shares
Investor Favorites Idea
Investor Favorites
Invested over 60 shares
Artificial Intelligence Idea
Artificial Intelligence
Invested few shares
Warren Buffett Holdings Idea
Warren Buffett Holdings
Invested few shares
Driverless Cars Idea
Driverless Cars
Invested over 200 shares
Hedge Favorites Idea
Hedge Favorites
Invested over 40 shares
FinTech Idea
FinTech
Invested over 20 shares
Momentum Idea
Momentum
Invested over 200 shares
Adviser Favorites Idea
Adviser Favorites
Invested few shares
Impulse Idea
Impulse
Invested over 200 shares
Baby Boomer Prospects Idea
Baby Boomer Prospects
Invested over 20 shares
Advertising Idea
Advertising
Invested few shares
Social Domain Idea
Social Domain
Invested few shares

More Resources for Passage Stock Analysis

Reviewing Passage Bio commonly begins with financial statements and performance trends. Ratios and trend metrics help frame Passage Bio's operating context. Outlined below are key reports that provide context for Passage Bio Stock:
Passage Bio has market cap of 27.3 M, ROE of -113.78%. Your Equity Center can help frame allocation decisions. The allocation includes a position in Passage Bio within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To understand the process of investing in Passage Stock, visit our How to Invest in Passage Bio guide.
Analysis related to Passage Bio should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
 Earnings Share
-14.35
 Return On Assets
-0.33
 Return On Equity
-1.14
Investors evaluate Passage Bio using market value and book value, each describing different facets of the business. Passage Bio's market capitalization is 27.3 M. A P/B ratio of 1.47 indicates the market values Passage Bio above its accounting book value. Enterprise value stands at 5.23 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for Passage Bio are related but not identical, and they can diverge across cycles. For Passage Bio, key inputs include a P/B ratio of 1.47, and ROE of -113.78%. Market price reflects the current exchange level formed by active bids and offers.